NEW YORK (
) is trading at unusually high volume Friday with 1.1 million shares changing hands. It is currently at 4.2 times its average daily volume and trading up 56 cents (+4.8%) at $12.15 as of 2 p.m. ET.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Osiris has a market cap of $364 million and is part of the
industry. Shares are up 107.1% year to date as of the close of trading on Thursday.
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Therapeutics and Biosurgery. The company has a P/E ratio of 38.2, below the average drugs industry P/E ratio of 39.6 and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Osiris as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. You can view the full
See all heavy volume stocks in our
or get investment ideas from our